Free tool
Drug Trial Radar: Dermatology
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
6
Active, not recruiting, industry sponsors, Dermatology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed212
6 trials
Showing 1 to 6, recently updated first.
- Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefensePivotal-lookingActive, not recruiting
Zura Bio IncIndustry
NCT06993610 · 247 participants · Start May 16, 2025 · Primary completion Sep 18, 2026
Drug: Tibulizumab Dose A; Tibulizumab Dose B · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 61 sites in all
- A Study Evaluating BFB759 in Moderate to Severe Hidradenitis SuppurativaPivotal-lookingActive, not recruiting
Bluefin Biomedicine, Inc.Industry
NCT07287644 · 210 participants (planned) · Start Nov 3, 2025 · Primary completion Aug 1, 2027
Drug: BFB759 · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Encino, California; Huntington Beach, California · 64 sites in all
- Evaluate RLS-1496 Topical Cream for Actinic KeratosisActive, not recruiting
Rubedo Life Sciences, Inc.Industry
NCT07340697 · 24 participants (planned) · Start Feb 3, 2026 · Primary completion May 27, 2026
Drug: RLS-1496 1.0% cream · For: Actinic Keratosis (AK)
Sites: Hot Springs, Arkansas; New Brighton, Minnesota; Omaha, Nebraska · 4 sites in all
- An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)Pivotal-lookingActive, not recruiting
TWi Biotechnology, Inc.Industry
NCT06073132 · 80 participants (planned) · Start Apr 4, 2024 · Primary completion Jun 10, 2026
Drug: AC-203; Vehicle · For: Generalized Epidermolysis Bullosa Simplex
Sites: Rancho Santa Margarita, California; Stanford, California; Aurora, Colorado · 30 sites in all
- Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingActive, not recruiting
Quoin PharmaceuticalsIndustry
NCT05521438 · 30 participants (planned) · Start Jun 23, 2022 · Primary completion Dec 30, 2025
Drug: QRX003-2% Lotion; QRX003-4% Lotion QAM and 2 more · For: Netherton Syndrome
Sites: San Diego, California; Indianapolis, Indiana; Quincy, Massachusetts · 5 sites in all
- Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisActive, not recruiting
Vanda PharmaceuticalsIndustry
NCT07065773 · 50 participants (planned) · Start May 5, 2025 · Primary completion Sep 2026
Drug: Trichostatin A · For: Onychomycosis of Toenail
Sites: Fremont, California; Denver, Colorado; New Brighton, Minnesota · 5 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.